Sepsis Diagnostics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Technology (Molecular Diagnostics, Microbiology, Immunoassay, and Other Technologies), By Product (Instruments, Assays and Reagents, and Other Products), By Diagnostic Method (Conventional Diagnostics and Automated Diagnostics), By Pathogen (Bacterial Sepsis, Fungal Sepsis, and Other Pathogens), By Region & Competition, 2021-2031F
The Global Sepsis Diagnostics Market is poised for significant expansion, projected to reach USD 1053.93 Million by 2031 from USD 657.19 Million in 2025, reflecting an 8.19% CAGR. This growth is primarily fueled by the increasing prevalence of healthcare-acquired infections, the expanding global geriatric population, and the urgent demand for rapid diagnostic results to reduce high mortality rates, given sepsis accounted for an estimated $62 billion in annual US hospitalization costs in 2025. Technological advancements in rapid molecular diagnostics are revolutionizing this sector by providing swift and accurate insights, moving beyond traditional blood cultures that take days to emerging host-response and molecular platforms delivering results in under an hour; for instance, Inflammatix received FDA clearance in January 2025 for its TriVerity Test System, which measures 29 genes to rapidly assess infection and sepsis risk. The escalating global incidence of sepsis, with an estimated 21.4 million sepsis-related deaths annually, alongside rising public awareness (75% in US adults by September 2025), further intensifies the need for robust diagnostic protocols and propels market expansion, facilitating better differentiation between bacterial and viral infections and optimizing antibiotic use.
Market Driver
Technological advancements in rapid molecular diagnostics are revolutionizing the Global Sepsis Diagnostics Market by addressing the critical need for speed and accuracy in clinical decision-making. Conventional blood cultures often require days to yield results, whereas emerging host-response and molecular platforms can now provide actionable insights in under an hour. This shift towards precision medicine is exemplified by recent regulatory milestones that validate the clinical utility of these next-generation tools, such as Inflammatix receiving FDA marketing authorization in January 2025 for its TriVerity Test System, a novel molecular diagnostic that measures the expression of 29 genes to rapidly evaluate infection and sepsis risk. Such innovations enable clinicians to distinguish between bacterial and viral infections more effectively, thereby reducing inappropriate antibiotic use and improving patient outcomes in critical care settings. The rising incidence of sepsis and hospital-acquired infections acts as a primary catalyst for market expansion, necessitating robust diagnostic protocols globally. The prevalence of sepsis has surged due to an aging population and the increasing complexity of medical interventions, creating a sustained demand for early detection capabilities to mitigate mortality. With an estimated 21.4 million sepsis-related deaths globally in a single year, this growing health crisis has triggered extensive public health efforts to improve recognition and management, directly influencing market adoption, with US adult awareness of 'sepsis' reaching a record high of 75% by September 2025, significantly driving the prioritization of diagnostic procurement in healthcare facilities.
Market Challenge
The substantial capital investment required for automated sepsis diagnostic systems presents a formidable barrier to market growth. These advanced platforms necessitate significant upfront costs for instrumentation, alongside ongoing expenses for maintenance and specialized reagents. Consequently, smaller healthcare facilities and community hospitals with restricted operational budgets often cannot justify the procurement of such expensive technology, effectively limiting the adoption of high-throughput diagnostic tools to large, well-funded medical centers and narrowing the addressable market for manufacturers. This economic constraint is particularly acute in developing regions where the clinical need is highest but financial resources are scarce. The disparity between the high cost of advanced diagnostics and the available healthcare infrastructure in emerging economies creates a significant impediment to widespread implementation. Approximately 85% of global sepsis cases occurred in low- and middle-income countries in 2025, where health system constraints and limited diagnostic capacity continue to hinder effective patient care. This disconnect between the geographical concentration of disease burden and the affordability of automated testing solutions restricts market expansion in regions that offer significant volume-based growth potential, further complicated by the lack of adequate reimbursement frameworks for new molecular technologies.
Market Trends
The Integration of Artificial Intelligence and Machine Learning for Early Prediction is shifting sepsis management from reactive treatment to predictive risk stratification. Advanced algorithmic models now analyze electronic health records in real-time to identify subtle physiological patterns hours before clinical deterioration, offering a significant advantage over traditional scoring systems that rely on late-stage vital signs. This capability to preemptively flag high-risk patients allows for earlier intervention bundles, directly addressing the time-sensitive nature of the condition; the implementation of a deep learning prediction tool was associated with a 17% relative decrease in in-hospital sepsis mortality by May 2025. Another key trend is the Miniaturization of Diagnostic Devices Using Microfluidic Technology, which enables the rapid assessment of host immune responses directly at the point of care. By leveraging micro-channels to measure the biophysical deformation of white blood cells, these platforms provide objective data on immune dysregulation in minutes, effectively bypassing the prolonged wait times associated with culture-based methods. This approach facilitates immediate, precision-guided triage, ensuring that antibiotics are administered effectively while preventing the progression of septic shock; for example, patients with suspected infection evaluated using microfluidic technology like the IntelliSep rapid sepsis diagnostic test had a 42% lower mortality rate compared to those receiving standard care by December 2025.
Key Market Players
In this report, the Global Sepsis Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Company Profiles: Detailed analysis of the major companies present in the Global Sepsis Diagnostics Market.
Available Customizations:
Global Sepsis Diagnostics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
Market Driver
Technological advancements in rapid molecular diagnostics are revolutionizing the Global Sepsis Diagnostics Market by addressing the critical need for speed and accuracy in clinical decision-making. Conventional blood cultures often require days to yield results, whereas emerging host-response and molecular platforms can now provide actionable insights in under an hour. This shift towards precision medicine is exemplified by recent regulatory milestones that validate the clinical utility of these next-generation tools, such as Inflammatix receiving FDA marketing authorization in January 2025 for its TriVerity Test System, a novel molecular diagnostic that measures the expression of 29 genes to rapidly evaluate infection and sepsis risk. Such innovations enable clinicians to distinguish between bacterial and viral infections more effectively, thereby reducing inappropriate antibiotic use and improving patient outcomes in critical care settings. The rising incidence of sepsis and hospital-acquired infections acts as a primary catalyst for market expansion, necessitating robust diagnostic protocols globally. The prevalence of sepsis has surged due to an aging population and the increasing complexity of medical interventions, creating a sustained demand for early detection capabilities to mitigate mortality. With an estimated 21.4 million sepsis-related deaths globally in a single year, this growing health crisis has triggered extensive public health efforts to improve recognition and management, directly influencing market adoption, with US adult awareness of 'sepsis' reaching a record high of 75% by September 2025, significantly driving the prioritization of diagnostic procurement in healthcare facilities.
Market Challenge
The substantial capital investment required for automated sepsis diagnostic systems presents a formidable barrier to market growth. These advanced platforms necessitate significant upfront costs for instrumentation, alongside ongoing expenses for maintenance and specialized reagents. Consequently, smaller healthcare facilities and community hospitals with restricted operational budgets often cannot justify the procurement of such expensive technology, effectively limiting the adoption of high-throughput diagnostic tools to large, well-funded medical centers and narrowing the addressable market for manufacturers. This economic constraint is particularly acute in developing regions where the clinical need is highest but financial resources are scarce. The disparity between the high cost of advanced diagnostics and the available healthcare infrastructure in emerging economies creates a significant impediment to widespread implementation. Approximately 85% of global sepsis cases occurred in low- and middle-income countries in 2025, where health system constraints and limited diagnostic capacity continue to hinder effective patient care. This disconnect between the geographical concentration of disease burden and the affordability of automated testing solutions restricts market expansion in regions that offer significant volume-based growth potential, further complicated by the lack of adequate reimbursement frameworks for new molecular technologies.
Market Trends
The Integration of Artificial Intelligence and Machine Learning for Early Prediction is shifting sepsis management from reactive treatment to predictive risk stratification. Advanced algorithmic models now analyze electronic health records in real-time to identify subtle physiological patterns hours before clinical deterioration, offering a significant advantage over traditional scoring systems that rely on late-stage vital signs. This capability to preemptively flag high-risk patients allows for earlier intervention bundles, directly addressing the time-sensitive nature of the condition; the implementation of a deep learning prediction tool was associated with a 17% relative decrease in in-hospital sepsis mortality by May 2025. Another key trend is the Miniaturization of Diagnostic Devices Using Microfluidic Technology, which enables the rapid assessment of host immune responses directly at the point of care. By leveraging micro-channels to measure the biophysical deformation of white blood cells, these platforms provide objective data on immune dysregulation in minutes, effectively bypassing the prolonged wait times associated with culture-based methods. This approach facilitates immediate, precision-guided triage, ensuring that antibiotics are administered effectively while preventing the progression of septic shock; for example, patients with suspected infection evaluated using microfluidic technology like the IntelliSep rapid sepsis diagnostic test had a 42% lower mortality rate compared to those receiving standard care by December 2025.
Key Market Players
- Abbott Laboratories
- DiaSorin SpA
- Becton, Dickinson, and Company
- BioMerieux Inc.
- F. Hoffmann-La Roche AG
- Danaher Corporation
- Thermo Fisher Scientific Inc
- Siemens Healthineers AG
- Seegene, Inc.
- Roche Diagnostics Corporation
In this report, the Global Sepsis Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
- Sepsis Diagnostics Market, By Technology
- Molecular Diagnostics
- Microbiology
- Immunoassay
- Other Technologies
- Sepsis Diagnostics Market, By Product
- Instruments
- Assays and Reagents
- Other Products
- Sepsis Diagnostics Market, By Diagnostic Method
- Conventional Diagnostics
- Automated Diagnostics
- Sepsis Diagnostics Market, By Pathogen
- Bacterial Sepsis
- Fungal Sepsis
- Other Pathogens
- Sepsis Diagnostics Market, By Region
- North America
- United States
- Canada
- Mexico
- Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- South America
- Brazil
- Argentina
- Colombia
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
Company Profiles: Detailed analysis of the major companies present in the Global Sepsis Diagnostics Market.
Available Customizations:
Global Sepsis Diagnostics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to five).
1. PRODUCT OVERVIEW
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. RESEARCH METHODOLOGY
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. EXECUTIVE SUMMARY
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. VOICE OF CUSTOMER
5. GLOBAL SEPSIS DIAGNOSTICS MARKET OUTLOOK
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Technology (Molecular Diagnostics, Microbiology, Immunoassay, Other Technologies)
5.2.2. By Product (Instruments, Assays and Reagents, Other Products)
5.2.3. By Diagnostic Method (Conventional Diagnostics, Automated Diagnostics)
5.2.4. By Pathogen (Bacterial Sepsis, Fungal Sepsis, Other Pathogens)
5.2.5. By Region
5.2.6. By Company (2025)
5.3. Market Map
6. NORTH AMERICA SEPSIS DIAGNOSTICS MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Technology
6.2.2. By Product
6.2.3. By Diagnostic Method
6.2.4. By Pathogen
6.2.5. By Country
6.3. North America: Country Analysis
6.3.1. United States Sepsis Diagnostics Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Technology
6.3.1.2.2. By Product
6.3.1.2.3. By Diagnostic Method
6.3.1.2.4. By Pathogen
6.3.2. Canada Sepsis Diagnostics Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Technology
6.3.2.2.2. By Product
6.3.2.2.3. By Diagnostic Method
6.3.2.2.4. By Pathogen
6.3.3. Mexico Sepsis Diagnostics Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Technology
6.3.3.2.2. By Product
6.3.3.2.3. By Diagnostic Method
6.3.3.2.4. By Pathogen
7. EUROPE SEPSIS DIAGNOSTICS MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Technology
7.2.2. By Product
7.2.3. By Diagnostic Method
7.2.4. By Pathogen
7.2.5. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Sepsis Diagnostics Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Technology
7.3.1.2.2. By Product
7.3.1.2.3. By Diagnostic Method
7.3.1.2.4. By Pathogen
7.3.2. France Sepsis Diagnostics Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Technology
7.3.2.2.2. By Product
7.3.2.2.3. By Diagnostic Method
7.3.2.2.4. By Pathogen
7.3.3. United Kingdom Sepsis Diagnostics Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Technology
7.3.3.2.2. By Product
7.3.3.2.3. By Diagnostic Method
7.3.3.2.4. By Pathogen
7.3.4. Italy Sepsis Diagnostics Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Technology
7.3.4.2.2. By Product
7.3.4.2.3. By Diagnostic Method
7.3.4.2.4. By Pathogen
7.3.5. Spain Sepsis Diagnostics Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Technology
7.3.5.2.2. By Product
7.3.5.2.3. By Diagnostic Method
7.3.5.2.4. By Pathogen
8. ASIA PACIFIC SEPSIS DIAGNOSTICS MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Technology
8.2.2. By Product
8.2.3. By Diagnostic Method
8.2.4. By Pathogen
8.2.5. By Country
8.3. Asia Pacific: Country Analysis
8.3.1. China Sepsis Diagnostics Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Technology
8.3.1.2.2. By Product
8.3.1.2.3. By Diagnostic Method
8.3.1.2.4. By Pathogen
8.3.2. India Sepsis Diagnostics Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Technology
8.3.2.2.2. By Product
8.3.2.2.3. By Diagnostic Method
8.3.2.2.4. By Pathogen
8.3.3. Japan Sepsis Diagnostics Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Technology
8.3.3.2.2. By Product
8.3.3.2.3. By Diagnostic Method
8.3.3.2.4. By Pathogen
8.3.4. South Korea Sepsis Diagnostics Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Technology
8.3.4.2.2. By Product
8.3.4.2.3. By Diagnostic Method
8.3.4.2.4. By Pathogen
8.3.5. Australia Sepsis Diagnostics Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Technology
8.3.5.2.2. By Product
8.3.5.2.3. By Diagnostic Method
8.3.5.2.4. By Pathogen
9. MIDDLE EAST & AFRICA SEPSIS DIAGNOSTICS MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Technology
9.2.2. By Product
9.2.3. By Diagnostic Method
9.2.4. By Pathogen
9.2.5. By Country
9.3. Middle East & Africa: Country Analysis
9.3.1. Saudi Arabia Sepsis Diagnostics Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Technology
9.3.1.2.2. By Product
9.3.1.2.3. By Diagnostic Method
9.3.1.2.4. By Pathogen
9.3.2. UAE Sepsis Diagnostics Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Technology
9.3.2.2.2. By Product
9.3.2.2.3. By Diagnostic Method
9.3.2.2.4. By Pathogen
9.3.3. South Africa Sepsis Diagnostics Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Technology
9.3.3.2.2. By Product
9.3.3.2.3. By Diagnostic Method
9.3.3.2.4. By Pathogen
10. SOUTH AMERICA SEPSIS DIAGNOSTICS MARKET OUTLOOK
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Technology
10.2.2. By Product
10.2.3. By Diagnostic Method
10.2.4. By Pathogen
10.2.5. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Sepsis Diagnostics Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Technology
10.3.1.2.2. By Product
10.3.1.2.3. By Diagnostic Method
10.3.1.2.4. By Pathogen
10.3.2. Colombia Sepsis Diagnostics Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Technology
10.3.2.2.2. By Product
10.3.2.2.3. By Diagnostic Method
10.3.2.2.4. By Pathogen
10.3.3. Argentina Sepsis Diagnostics Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Technology
10.3.3.2.2. By Product
10.3.3.2.3. By Diagnostic Method
10.3.3.2.4. By Pathogen
11. MARKET DYNAMICS
11.1. Drivers
11.2. Challenges
12. MARKET TRENDS & DEVELOPMENTS
12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments
13. GLOBAL SEPSIS DIAGNOSTICS MARKET: SWOT ANALYSIS
14. PORTER'S FIVE FORCES ANALYSIS
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products
15. COMPETITIVE LANDSCAPE
15.1. Abbott Laboratories
15.1.1. Business Overview
15.1.2. Products & Services
15.1.3. Recent Developments
15.1.4. Key Personnel
15.1.5. SWOT Analysis
15.2. DiaSorin SpA
15.3. Becton, Dickinson, and Company
15.4. BioMerieux Inc.
15.5. F. Hoffmann-La Roche AG
15.6. Danaher Corporation
15.7. Thermo Fisher Scientific Inc
15.8. Siemens Healthineers AG
15.9. Seegene, Inc.
15.10. Roche Diagnostics Corporation
16. STRATEGIC RECOMMENDATIONS
17. ABOUT US & DISCLAIMER
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. RESEARCH METHODOLOGY
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. EXECUTIVE SUMMARY
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. VOICE OF CUSTOMER
5. GLOBAL SEPSIS DIAGNOSTICS MARKET OUTLOOK
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Technology (Molecular Diagnostics, Microbiology, Immunoassay, Other Technologies)
5.2.2. By Product (Instruments, Assays and Reagents, Other Products)
5.2.3. By Diagnostic Method (Conventional Diagnostics, Automated Diagnostics)
5.2.4. By Pathogen (Bacterial Sepsis, Fungal Sepsis, Other Pathogens)
5.2.5. By Region
5.2.6. By Company (2025)
5.3. Market Map
6. NORTH AMERICA SEPSIS DIAGNOSTICS MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Technology
6.2.2. By Product
6.2.3. By Diagnostic Method
6.2.4. By Pathogen
6.2.5. By Country
6.3. North America: Country Analysis
6.3.1. United States Sepsis Diagnostics Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Technology
6.3.1.2.2. By Product
6.3.1.2.3. By Diagnostic Method
6.3.1.2.4. By Pathogen
6.3.2. Canada Sepsis Diagnostics Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Technology
6.3.2.2.2. By Product
6.3.2.2.3. By Diagnostic Method
6.3.2.2.4. By Pathogen
6.3.3. Mexico Sepsis Diagnostics Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Technology
6.3.3.2.2. By Product
6.3.3.2.3. By Diagnostic Method
6.3.3.2.4. By Pathogen
7. EUROPE SEPSIS DIAGNOSTICS MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Technology
7.2.2. By Product
7.2.3. By Diagnostic Method
7.2.4. By Pathogen
7.2.5. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Sepsis Diagnostics Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Technology
7.3.1.2.2. By Product
7.3.1.2.3. By Diagnostic Method
7.3.1.2.4. By Pathogen
7.3.2. France Sepsis Diagnostics Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Technology
7.3.2.2.2. By Product
7.3.2.2.3. By Diagnostic Method
7.3.2.2.4. By Pathogen
7.3.3. United Kingdom Sepsis Diagnostics Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Technology
7.3.3.2.2. By Product
7.3.3.2.3. By Diagnostic Method
7.3.3.2.4. By Pathogen
7.3.4. Italy Sepsis Diagnostics Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Technology
7.3.4.2.2. By Product
7.3.4.2.3. By Diagnostic Method
7.3.4.2.4. By Pathogen
7.3.5. Spain Sepsis Diagnostics Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Technology
7.3.5.2.2. By Product
7.3.5.2.3. By Diagnostic Method
7.3.5.2.4. By Pathogen
8. ASIA PACIFIC SEPSIS DIAGNOSTICS MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Technology
8.2.2. By Product
8.2.3. By Diagnostic Method
8.2.4. By Pathogen
8.2.5. By Country
8.3. Asia Pacific: Country Analysis
8.3.1. China Sepsis Diagnostics Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Technology
8.3.1.2.2. By Product
8.3.1.2.3. By Diagnostic Method
8.3.1.2.4. By Pathogen
8.3.2. India Sepsis Diagnostics Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Technology
8.3.2.2.2. By Product
8.3.2.2.3. By Diagnostic Method
8.3.2.2.4. By Pathogen
8.3.3. Japan Sepsis Diagnostics Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Technology
8.3.3.2.2. By Product
8.3.3.2.3. By Diagnostic Method
8.3.3.2.4. By Pathogen
8.3.4. South Korea Sepsis Diagnostics Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Technology
8.3.4.2.2. By Product
8.3.4.2.3. By Diagnostic Method
8.3.4.2.4. By Pathogen
8.3.5. Australia Sepsis Diagnostics Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Technology
8.3.5.2.2. By Product
8.3.5.2.3. By Diagnostic Method
8.3.5.2.4. By Pathogen
9. MIDDLE EAST & AFRICA SEPSIS DIAGNOSTICS MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Technology
9.2.2. By Product
9.2.3. By Diagnostic Method
9.2.4. By Pathogen
9.2.5. By Country
9.3. Middle East & Africa: Country Analysis
9.3.1. Saudi Arabia Sepsis Diagnostics Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Technology
9.3.1.2.2. By Product
9.3.1.2.3. By Diagnostic Method
9.3.1.2.4. By Pathogen
9.3.2. UAE Sepsis Diagnostics Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Technology
9.3.2.2.2. By Product
9.3.2.2.3. By Diagnostic Method
9.3.2.2.4. By Pathogen
9.3.3. South Africa Sepsis Diagnostics Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Technology
9.3.3.2.2. By Product
9.3.3.2.3. By Diagnostic Method
9.3.3.2.4. By Pathogen
10. SOUTH AMERICA SEPSIS DIAGNOSTICS MARKET OUTLOOK
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Technology
10.2.2. By Product
10.2.3. By Diagnostic Method
10.2.4. By Pathogen
10.2.5. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Sepsis Diagnostics Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Technology
10.3.1.2.2. By Product
10.3.1.2.3. By Diagnostic Method
10.3.1.2.4. By Pathogen
10.3.2. Colombia Sepsis Diagnostics Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Technology
10.3.2.2.2. By Product
10.3.2.2.3. By Diagnostic Method
10.3.2.2.4. By Pathogen
10.3.3. Argentina Sepsis Diagnostics Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Technology
10.3.3.2.2. By Product
10.3.3.2.3. By Diagnostic Method
10.3.3.2.4. By Pathogen
11. MARKET DYNAMICS
11.1. Drivers
11.2. Challenges
12. MARKET TRENDS & DEVELOPMENTS
12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments
13. GLOBAL SEPSIS DIAGNOSTICS MARKET: SWOT ANALYSIS
14. PORTER'S FIVE FORCES ANALYSIS
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products
15. COMPETITIVE LANDSCAPE
15.1. Abbott Laboratories
15.1.1. Business Overview
15.1.2. Products & Services
15.1.3. Recent Developments
15.1.4. Key Personnel
15.1.5. SWOT Analysis
15.2. DiaSorin SpA
15.3. Becton, Dickinson, and Company
15.4. BioMerieux Inc.
15.5. F. Hoffmann-La Roche AG
15.6. Danaher Corporation
15.7. Thermo Fisher Scientific Inc
15.8. Siemens Healthineers AG
15.9. Seegene, Inc.
15.10. Roche Diagnostics Corporation
16. STRATEGIC RECOMMENDATIONS
17. ABOUT US & DISCLAIMER
